Bioversys AG

BIOV · SW · Healthcare / Biotechnology

23.40CHF-0.50 (-2.09%)

Price History

Full chart

Market Stats

Previous Close23.90

Open23.70

Day Range23.40 – 23.70

52-Week Range21.20 – 30.70

Volume594

Market Cap158.07M

P/E (TTM)0.00

Forward P/E0.00

EPS-4.50

Dividend Yield0.00%

50-Day Avg26.65

200-Day Avg26.23

About

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Marc Gitzinger
Employees38
HeadquartersHochbergerstrasse 60c, Basel, Switzerland, 4057, Switzerland
Websitehttps://www.bioversys.com

Leadership

Dr. Marc GitzingerCEO, Co-founder & Director · b. 1981
Mr. Hernan Santiago Levett CPAChief Financial Officer · b. 1975
Dr. Daniel RitzChief Scientific Officer · b. 1964
Ms. Anca CighiHead of Investor Relations & Communications
Ms. Fiona Gao EMBA, L.L.M.Head of Legal
Mr. Philipp SchmidHead of Finance
Dr. Jonathan James ButcherHead of Business Development & Alliance Management
Dr. Glenn E. DaleChief Development Officer · b. 1963
Dr. Jurgen JagerHead of Chemistry, Manufacturing & Controls
Dr. Alessia MichelottiHead of Chemistry

Financials

Income Statement

Currency: CHF	2024-12-31	2025-12-31
Total Revenue	0	800.00K
Cost of Revenue	3.95M	3.89M
Gross Profit	-3.95M	-3.09M
Gross Margin	-	-386.63%
Operating Expense	14.77M	16.87M
Operating Income	-18.72M	-19.96M
Operating Margin	-	-2495.38%
EBITDA	-17.40M	-20.44M
EBITDA Margin	-	-2555.00%
Net Income	-18.72M	-21.83M
Net Income Margin	-	-2728.75%
R&D	12.95M	16.50M
R&D as % of Total Revenue	-	2062.75%
Interest Expense	1.04M	1.08M
Interest Expense % of Total Revenue	-	134.63%

Balance Sheet

Currency: CHF	2024-12-31	2025-12-31
Total Assets	34.96M	90.64M
Total Liabilities	24.27M	30.82M
Total Equity	10.68M	59.81M
Cash	26.62M	82.50M

Cash Flow

Currency: CHF	2024-12-31	2025-12-31
Operating Cash Flow	-15.57M	-21.95M
Capital Expenditure	38.00K	216.00K
Free Cash Flow	-15.61M	-22.16M
FCF to OCF	100.24%	100.98%

Earnings

Report Date	Sep 10, 2025	Dec 3, 2025	Dec 31, 2025	Apr 1, 2026	Jun 30, 2026
EPS Estimate	0.00	-0.99	-1.07	-1.07	-1.71
EPS Actual	-2.05	-0.99	-	0.00	-
Surprise	-	0.00%	-	100.00%	-
Timing	-	-	-	-	-

Key Statistics & Ratios

Market Cap158.07M

Enterprise Value100.98M

Trailing P/E0.00

Forward P/E0.00

Price / Sales34.19

Price / Book3.30

EPS-4.50

Book Value7.66

Revenue (TTM)4.62M

Gross Profit (TTM)4.62M

EBITDA-25.04M

Profit Margin0.00%

Operating Margin-722.37%

Return on Equity-46.05%

Return on Assets-18.33%

Shares Outstanding5.85M

Shares Float3.87M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%